Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters
January 27 2005 - 6:00AM
PR Newswire (US)
Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option
by Underwriters SAN DIEGO, Jan. 27 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced the exercise by
its underwriters of an over-allotment option to purchase 1,200,000
shares of common stock associated with its follow-on stock offering
which priced on January 20, 2005. Including the over-allotment
shares, the offering will total 9,200,000 shares at $22.00 per
share, resulting in expected net proceeds to the company of
approximately $190.5 million. Morgan Stanley & Co. Incorporated
acted as the sole book running and joint lead manager for the
offering. Goldman, Sachs & Co. acted as joint lead manager of
the offering. Co-managers for the offering were Banc of America
Securities LLC, J.P. Morgan Securities Inc., and Wachovia Capital
Markets, LLC. This announcement is neither an offer to sell nor a
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state. A registration statement
relating to these securities has been filed with and has been
declared effective by the Securities and Exchange Commission. The
common stock is being offered in connection with the distribution
by the issuer and represents a new financing. Amylin
Pharmaceuticals is committed to improving the lives of people with
diabetes and other metabolic disorders through the development and
commercialization of innovative, cost-effective medicines. Copies
of the final prospectus supplement may be obtained from the
Prospectus Departments of Morgan Stanley & Co. Incorporated
(1585 Broadway, New York, New York 10036, phone 212-761-6775, fax
212-761-0211), Goldman, Sachs & Co. (Attn: Prospectus
Department, 85 Broad Street, New York, New York 10004, phone
212-902-1171, fax 212-902-9316), Banc of America Securities LLC (9
West 57th Street, New York, NY 10019, phone 888-583-8900), J.P.
Morgan Securities Inc. (1 Chase Manhattan Plaza, Floor 5B, New
York, New York 10081, phone 212-552-5164) and Wachovia Capital
Markets, LLC (7 St. Paul Street, Baltimore, Maryland 21202, phone
443-263-6400, fax 443-263-6894). DATASOURCE: Amylin
Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President of
Finance and Chief Financial Officer of Amylin Pharmaceuticals,
+1-858-552-2200 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024